Latest News
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
23 September 2026 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) declared on Wednesday that it has received European Commission approval for Trixeo Aerosphere as a maintenance treatment for asthma in patients aged 12 and ov...
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
23 September 2026 - Canadian life sciences company Ondine Biomedical Inc. (AIM: OBI) reported on Wednesday that five Southern Ontario hospitals are deploying the company's Steriwave nasal photodisinfection across approximately 5,000 annual ortho...
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
23 September 2026 - RNA-targeted medicine company Ionis Pharmaceuticals Inc (Nasdaq: IONS) and healthcare company Roche on Wednesday reported positive interim results from the Phase 3 IMAgINATION study of investigational sefaxersen in adults with pri...
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
23 September 2026 - X-Chem, a US-based global company involved in innovative drug discovery services, announced on Tuesday the achievement of a milestone following Relay Therapeutics' initiation of a Phase 3 clinical trial of a drug candidate de...
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
23 September 2026 - BoomRay Pharmaceuticals Co., Ltd., a China-based clinical-stage biotechnology company involved in innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, announced on Tuesday that it has entere...